Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 11/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14833517 | 1.00 | MEN1 (0.49) | MEN1KMT2ACCR2KCNH2DRD4 | |
| SCHEMBL14833315 | 0.88 | MEN1 (0.49) | MEN1KMT2ACCR2KCNH2DRD4 | |
| SCHEMBL14815236 | 0.88 | MEN1 (0.49) | MEN1KMT2ACCR2KCNH2DRD4 | |
| SCHEMBL14815069 | 0.88 | CCR2 (0.54) | MEN1KMT2ACCR2KCNH2HPGD | |
| SCHEMBL14833216 | 0.88 | CCR2 (0.54) | MEN1KMT2ACCR2KCNH2HPGD | |
| SCHEMBL14815282 | 0.86 | HSD11B1 (0.53) | MEN1KMT2ACCR2KCNH2HPGD | |
| SCHEMBL14833207 | 0.86 | HSD11B1 (0.53) | MEN1KMT2ACCR2KCNH2HPGD | |
| SCHEMBL14814550 | 0.85 | KMT2A (0.50) | MEN1KMT2ACCR2HPGDHSD11B1 | |
| SCHEMBL14830396 | 0.85 | KMT2A (0.50) | MEN1KMT2ACCR2HPGDHSD11B1 | |
| SCHEMBL14815167 | 0.85 | KMT2A (0.50) | MEN1KMT2ACCR2HPGDHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669255-B2 | Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers | ABBVIE INC. (US) | 2014-03-11 | — | — | US | claimed |
| US-8669255-B2 | Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers | ABBVIE INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | MEN1 1008/4885KMT2A 2999/4885CCR2 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.